A joint venture for the development of advanced surgical biomedical materials in volves Wilmington, DE-based DuPont and Netherlands-based DSM.

Under the agreement, both companies will share a 50% interest in the joint venture dubbed Actamax. Surgical Materials. Actamax will address market needs for surgical sealants, adhesion barriers, and tissue adhesives, based on several patent-protected biodegradable hydrogel technologies.